The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
FY Kreidieh, HA Tawbi - Therapeutic advances in medical …, 2023 - journals.sagepub.com
Despite major advances with immunotherapy and targeted therapy in the past decade,
metastatic melanoma continues to be a deadly disease for close to half of all patients. Over …
metastatic melanoma continues to be a deadly disease for close to half of all patients. Over …
Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma
HA Tawbi, D Schadendorf, EJ Lipson… - … England Journal of …, 2022 - Mass Medical Soc
Background Lymphocyte-activation gene 3 (LAG-3) and programmed death 1 (PD-1) are
distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination …
distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination …
Development of a LAG-3 immunohistochemistry assay for melanoma
L Johnson, B McCune, D Locke, C Hedvat… - Journal of Clinical …, 2023 - jcp.bmj.com
Aims A robust immunohistochemistry (IHC) assay was developed to detect lymphocyte-
activation gene 3 (LAG-3) expression by immune cells (ICs) in tumour tissues. LAG-3 is an …
activation gene 3 (LAG-3) expression by immune cells (ICs) in tumour tissues. LAG-3 is an …
Construction of dual functional CuAl-LDHs nanocomposite loaded with IGF2BP3 siRNA for enhanced therapy of gastric cancer
H Li, Y Zhang, B Huang, F Yang, Q Ma, X Wang… - Chemical Engineering …, 2024 - Elsevier
Gastric cancer (GC) is a prevalent malignancy in China, necessitating innovative treatments.
Recent advancements in nucleic acid drugs, particularly small interfering RNAs (siRNAs) …
Recent advancements in nucleic acid drugs, particularly small interfering RNAs (siRNAs) …
First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study
S Hegewisch-Becker, G Mendez, J Chao… - Journal of Clinical …, 2024 - ascopubs.org
PURPOSE Open-label phase II study (RELATIVITY-060) to investigate the efficacy and
safety of first-line nivolumab, a PD-1–blocking antibody, plus relatlimab, a lymphocyte …
safety of first-line nivolumab, a PD-1–blocking antibody, plus relatlimab, a lymphocyte …
[PDF][PDF] Inmunoterapia en Melanoma: Rol de TIGIT y LAG-3 en el microambiente inmune antitumoral.
GC Gaona Neira, SD Salazar Prieto… - Ciencia en …, 2023 - revistas.uptc.edu.co
El melanoma es un tumor maligno que surge por alteraciones de los melanocitos, que
desencadenan la pérdida de control de los mecanismos de crecimiento y proliferación …
desencadenan la pérdida de control de los mecanismos de crecimiento y proliferación …